Biotech · Private company · Saint Louis, MO, US
Fimbrion Therapeutics, Inc.
Track this companyFree. Adds Fimbrion Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous MycobacteriaFiscal year 2026 · $300KNIH RePORTER 5R43AI188991-02 · fetched Nov 12, 2026
- Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas InfectionsFiscal year 2026 · $300KNIH RePORTER 5R43AI192169-02 · fetched Nov 12, 2026
- Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for TuberculosisFiscal year 2026 · $300KNIH RePORTER 5R43AI192175-02 · fetched Nov 12, 2026
- Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous MycobacteriaFiscal year 2025 · $300KNIH RePORTER 1R43AI188991-01 · fetched Nov 12, 2026
- Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas InfectionsFiscal year 2025 · $300KNIH RePORTER 1R43AI192169-01 · fetched Nov 12, 2026
- Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for TuberculosisFiscal year 2025 · $300KNIH RePORTER 1R43AI192175-01 · fetched Nov 12, 2026
- Thiazolino-Pyridone Compounds as Novel Drugs for TuberculosisFiscal year 2024 · $300KNIH RePORTER 5R43AI172559-02 · fetched Nov 12, 2026
- FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract InfectionsFiscal year 2024 · $300KNIH RePORTER 5R43AI174482-02 · fetched Nov 12, 2026
- Heterocyclic Inhibitors of QcrB as Novel Drugs for TuberculosisFiscal year 2024 · $995KNIH RePORTER 5R44AI149833-05 · fetched Nov 12, 2026